Feasibility of [18F]FSPG PET for Early Response Assessment to Combined Blockade of EGFR and Glutamine Metabolism in Wild-Type KRAS Colorectal Cancer
Tomography · 2023
DOI: 10.3390/tomography9020041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tomography, 2023. Verfasst von Seong-Woo Bae und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Glutaminase, Colorectal Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NIH.
Abstract (Originalsprache)
Early response assessment is critical for personalizing cancer therapy. Emerging therapeutic regimens with encouraging results in the wild-type (WT) KRAS colorectal cancer (CRC) setting include inhibitors of epidermal growth factor receptor (EGFR) and glutaminolysis. Towards predicting clinical outcome, this preclinical study evaluated non-invasive positron emission tomography (PET) with (4S)-4-(3-[18F]fluoropropyl)-L-glutamic acid ([18F]FSPG) in treatment-sensitive and treatment-resistant WT KRAS CRC patient-derived xenografts (PDXs). Tumor-bearing mice were imaged with [18F]FSPG PET before and one week following the initiation of treatment with either EGFR-targeted monoclonal antibody (mAb) therapy, glutaminase inhibitor therapy, or the combination. Imaging was correlated with tumor volume and histology. In PDX that responded to therapy, [18F]FSPG PET was significantly decreased from baseline at 1-week post-therapy, prior to changes in tumor volume. In contrast, [18F]FSPG PET was not decreased in non-responding PDX. These data suggest that [18F]FSPG PET may serve as an early metric of response to EGFR and glutaminase inhibition in the WT KRAS CRC setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
- Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center, 1161 21st Avenue South, Medical Center North, AA-1105, Nashville, TN 37232, USA.
- Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, 1161 21st Avenue South, Medical Center North, AA-1105, Nashville, TN 37232, USA.
- Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, 1161 21st Avenue South, Medical Center North, Nashville, TN 37232, USA.
ORCID-Profile: Seong-Woo Bae, Dimitra K Georgiou
Förderung
- NCI NIH HHS
- NIH HHS
- NIH
- Cancer Prevention Research Institute of Texas
Zitieren
APA
Bae, S. W., Wang, J., Georgiou, D. K., Wen, X., Cohen, A. S., Geng, L., Tantawy, M. N., & Manning, H. C. (2023). Feasibility of [18F]FSPG PET for Early Response Assessment to Combined Blockade of EGFR and Glutamine Metabolism in Wild-Type KRAS Colorectal Cancer. Tomography. https://doi.org/10.3390/tomography9020041
Vancouver
Bae SW, Wang J, Georgiou DK, Wen X, Cohen AS, Geng L, et al. Feasibility of [18F]FSPG PET for Early Response Assessment to Combined Blockade of EGFR and Glutamine Metabolism in Wild-Type KRAS Colorectal Cancer. Tomography. 2023. doi:10.3390/tomography9020041
BibTeX
@article{Bae2023,
author = {Bae, Seong-Woo and Wang, Jianbo and Georgiou, Dimitra K and Wen, Xiaoxia and Cohen, Allison S and Geng, Ling and Tantawy, Mohammed Noor and Manning, H Charles},
title = {Feasibility of [18F]FSPG PET for Early Response Assessment to Combined Blockade of EGFR and Glutamine Metabolism in Wild-Type KRAS Colorectal Cancer},
journal = {Tomography},
year = {2023},
doi = {10.3390/tomography9020041}
}
EUVIMED